Building a breathing test platform to detect and track COPD and asthma
Tests an impulse oscillometry breathing test to detect COPD and asthma in adults.
Plain-language title generated from the registry record
Registry title: Construction and Validation of an Impulse Oscillometry (IOS)-Based Platform for Screening, Diagnosis, and Management of Chronic Airway Diseases
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07910409, who can take part
Where in China
- eijing Chao-Yang Hospital, Capital Medical UniversityBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Chao Yang Hospital
- Trial code
- NCT07910409
- Record updated
- 2 November 2026
- Original description
This is a multicenter, observational study aiming to construct and validate an Impulse Oscillometry (IOS)-based platform for the screening, diagnosis, and management of chronic airway diseases (COPD and asthma). The study consists of two phases. Phase 1 is a cross-sectional study to build and validate diagnostic models for COPD and asthma using IOS parameters, with respiratory specialists' clinical diagnosis as the gold standard. Phase 2 is a 48-week prospective cohort study to develop a prognostic model for predicting acute exacerbation risk based on IOS parameters. Approximately 2,800 participants will be enrolled from hospitals, physical examination centers, and community health centers across China. The results will provide evidence for the clinical application of IOS technology in chronic airway disease management.Read full original descriptionShow less
Construction and Validation of an Impulse Oscillometry (IOS)-Based Platform for Screening, Diagnosis, and Management of Chronic Airway Diseases
This is a multicenter, observational study aiming to construct and validate an Impulse Oscillometry (IOS)-based platform for the screening, diagnosis, and management of chronic airway diseases (COPD and asthma). The study consists of two phases. Phase 1 is a cross-sectional study to build and validate diagnostic models for COPD and asthma using IOS parameters, with respiratory specialists' clinical diagnosis as the gold standard. Phase 2 is a 48-week prospective cohort study to develop a prognostic model for predicting acute exacerbation risk based on IOS parameters. Approximately 2,800 participants will be enrolled from hospitals, physical examination centers, and community health centers across China. The results will provide evidence for the clinical application of IOS technology in chronic airway disease management.
Inclusion: Age 18 to 80 years; Phase 1: Participants from respiratory and critical care medicine outpatient clinics, physical examination centers, and community health centers; conscious, with basic communication and comprehension ability, able to cooperate with questionnaires and IOS/spirometry examinations; willing to sign written informed consent; Phase 2: Patients with confirmed stable COPD (meeting GOLD criteria) or asthma (meeting GINA criteria); stable disease defined as no acute exacerbation within the past 4 weeks, without the need for systemic glucocorticoids or increased routine medication; willing to sign written informed consent.
Exclusion: Phase 1: Respiratory infection within the past 4 weeks; other severe pulmonary diseases affecting lung function (e.g., active tuberculosis, extensive bronchiectasis, pulmonary fibrosis, chest wall deformity, lung cancer); severe dysfunction of heart, brain, liver, or kidney (e.g., NYHA class III-IV, severe arrhythmia, uremia) or uncontrolled malignancy; cognitive impairment or psychiatric disorders; pregnancy or lactation; contraindications to pulmonary function tests; Phase 2: Comorbid severe respiratory diseases (e.g., bronchiectasis, pulmonary fibrosis, lung cancer, active tuberculosis); severe heart, liver, or kidney dysfunction (e.g., NYHA class III-IV, end-stage liver disease, dialysis-dependent renal disease); conditions affecting pulmonary function test accuracy (e.g., chest wall deformity, pneumothorax, recent thoracic or abdominal surgery); severe cognitive impairment, psychiatric disorders, or communication barriers; planned relocation within 1 year or inability to complete regular follow-up; pregnancy or lactation.